Efficacy and safety of long-term zonisamide 25 mg/day treatment for parkinsonism in patients with dementia with Lewy bodies : a post-hoc analysis of phase III clinical trial

Toshinari Odawara¹⁾, Masaaki Tagawa²⁾, Kenji Kochi³⁾, Kazuko Hasegawa⁴⁾

¹⁾Health Management Center, Yokohama City University
²⁾Medical Affairs, Sumitomo Pharma Co., Ltd.
³⁾Data Science, Sumitomo Pharma Co., Ltd.
⁴⁾Neurology, National Hospital Organization, Sagamihara National Hospital

Zonisamide has been approved as an agent for the treatment of parkinsonism accompanying dementia with Lewy bodies in July 2018 and is currently available at a dose of 25 mg/day in Japan.　In this present study, to examine the efficacy and safety of long-term treatment with zonisamide 25 mg/day for parkinsonism in patients with dementia with Lewy bodies, we performed a post-hoc analysis using the data from 48 subjects who took only the approved dose of 25 mg/day throughout the 52-week trial period in a phase III trial.

Key words:zonisamide, dementia with Lewy bodies, parkinsonism, approved dosage, long-term treatment, post-hoc analysis

Address correspondence to Dr. Toshinari Odawara, Health Management Center, Yokohama City University (22-2 Seto, Kanazawa-ku, Yokohama 236-0027, Japan)